Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

The stock market can be quite turbulent. Growth stocks, while having tremendous potential, can also be risky, as we have seen this month. The once-hyped AI growth stocks plummeted as investors failed ...

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the ...

Pfizer Inc. PFE shares are trending on Wednesday following the U.S. Food and Drug Administration’s (FDA) full approval of the BRAFTOVI combination regimen for treating metastatic colorectal cancer.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. On February 25, ...

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...

A Maryland biotech raised its revenue guidance for the year, thanks largely to some hefty pharma deals it’s betting will pay off.

Learn more about whether Celldex Therapeutics, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.